Adaptive Biotechnologies Corporation $ADPT Stock Position Reduced by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC trimmed its position in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 76.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,609 shares of the company’s stock after selling 110,331 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in Adaptive Biotechnologies were worth $392,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ADPT. Vanguard Group Inc. boosted its holdings in Adaptive Biotechnologies by 4.0% in the first quarter. Vanguard Group Inc. now owns 11,143,428 shares of the company’s stock worth $82,796,000 after purchasing an additional 428,540 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Adaptive Biotechnologies by 801.6% in the 1st quarter. Ameriprise Financial Inc. now owns 6,642,476 shares of the company’s stock worth $49,355,000 after buying an additional 5,905,756 shares during the last quarter. Braidwell LP acquired a new position in shares of Adaptive Biotechnologies in the 1st quarter valued at about $35,692,000. Driehaus Capital Management LLC boosted its holdings in shares of Adaptive Biotechnologies by 154.4% in the 1st quarter. Driehaus Capital Management LLC now owns 2,152,335 shares of the company’s stock valued at $15,992,000 after buying an additional 1,306,164 shares during the period. Finally, Iron Triangle Partners LP bought a new stake in shares of Adaptive Biotechnologies during the 1st quarter valued at about $15,856,000. 99.17% of the stock is owned by institutional investors and hedge funds.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $14.10 on Monday. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -17.19 and a beta of 2.09. Adaptive Biotechnologies Corporation has a 1 year low of $4.27 and a 1 year high of $17.89. The business has a fifty day moving average of $15.01 and a 200-day moving average of $12.35.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.01. The business had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. Adaptive Biotechnologies had a negative net margin of 59.07% and a negative return on equity of 60.93%. The company’s quarterly revenue was up 102.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.22) earnings per share. On average, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Morgan Stanley raised their target price on shares of Adaptive Biotechnologies from $11.00 to $16.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, October 8th. Piper Sandler upped their price objective on Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 15th. Wall Street Zen upgraded Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Adaptive Biotechnologies has an average rating of “Moderate Buy” and a consensus target price of $16.56.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 86,161 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $14.73, for a total value of $1,269,151.53. Following the completion of the sale, the chief executive officer directly owned 2,873,088 shares in the company, valued at $42,320,586.24. This represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Harlan S. Robins sold 10,000 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $14.82, for a total value of $148,200.00. Following the transaction, the insider directly owned 1,269,524 shares of the company’s stock, valued at approximately $18,814,345.68. The trade was a 0.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 99,265 shares of company stock valued at $1,463,380 over the last quarter. Insiders own 6.40% of the company’s stock.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.